# CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

> **NCT04097444** · PHASE2 · UNKNOWN · sponsor: **Chugai Pharmaceutical** · enrollment: 112 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** 5-fluorouracil
- **DRUG:** Leucovorin calcium
- **DRUG:** Irinotecan hydrochloride
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04097444
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-11
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2019-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097444, "CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04097444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*